<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>69</patient-age><report-id>SE-NOVOPROD-369386</report-id><gender>male</gender><reactions><reaction>Transaminasis elevated</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>NovoNorm</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ZYTIGA</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Product used for unknown indication</indication><indication>Prostate cancer metastatic</indication></indications><patient-age>69</patient-age><outcomes/><country>Sweden</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>170159_050</messagenumb>
		<messagesenderidentifier>NOVOPROD</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151548</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>SE-NOVOPROD-369386</safetyreportid>
		<primarysourcecountry>SE</primarysourcecountry>
		<occurcountry>SE</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-17</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-17</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>E2b Differences Report</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb>ID 124898</authoritynumb>
		<primarysource>
			<reportercountry>SE</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVOPROD</senderorganization>
			<senderdepartment>Product Safety and Clinical Quality Assurance</senderdepartment>
			<sendergivename>Novo</sendergivename>
			<sendermiddlename>Nordisk</sendermiddlename>
			<senderfamilyname>Inc.</senderfamilyname>
			<senderstreetaddress>100 College Road West</senderstreetaddress>
			<sendercity>Princeton</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>08540</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>6099875831</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>6099878480</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>NNPI_AE_REPORTING@NOVONORDISK.COM</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDAEDI.CDER</receiverdepartment>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3018276504</receivertel>
			<receivertelcountrycode>1</receivertelcountrycode>
			<receiveremailaddress>WTaylor@OC.FDA.GOV</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>69</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientagegroup>6</patientagegroup>
			<patientsex code="1">Male</patientsex>
			<resultstestsprocedures>On an unknown date laboratory tests included: Alanine aminotransferase 4.43 (units unspecified) ref interval is less than 1.20 and test results has been 4.43 - 1.73 - 3.71.- ukat/L)), Aspartate aminotransferase 2.01 (units unspecified) ref interval is less than 0.76 and test result has been 2.01 - 0.78 - 1.88  ukat/L)).</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Prostate cancer metastatic</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Transaminasis elevated</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Transaminases increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Transaminases increased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120808</reactionstartdate>
				<reactionfirsttime>317</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>Alanine aminotransferase</testname>
				<testresult>4.43</testresult>
				<testunit>N/A</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Aspartate aminotransferase</testname>
				<testresult>2.01</testresult>
				<testunit>N/A</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>NovoNorm</medicinalproduct>
				<obtaindrugcountry>SE</obtaindrugcountry>
				<drugbatchnumb>UNKNOWN</drugbatchnumb>
				<drugauthorizationnumb>20-741</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="065">Unknown</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Product used for unknown indication</drugindication>
				<actiondrug code="2">Dose Reduced</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>Repaglinide</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Transaminases increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Transaminases increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>NovoNorm</medicinalproduct>
				<obtaindrugcountry>SE</obtaindrugcountry>
				<drugbatchnumb>Unknown</drugbatchnumb>
				<drugauthorizationnumb>20-741</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="065">Unknown</drugadministrationroute>
				<actiondrug code="2">Dose Reduced</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>Repaglinide</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Transaminases increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Reportable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Transaminases increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ZYTIGA</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute code="065">Unknown</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Prostate cancer metastatic</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-09-26</drugstartdate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ABIRATERONE ACETATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ZYTIGA</medicinalproduct>
				<drugbatchnumb>Unknown</drugbatchnumb>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute code="065">Unknown</drugadministrationroute>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-07</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ABIRATERONE ACETATE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This serious regulatory authority case was received through the <Semaphore x="2597467" class="Race" value="Swedish" score="1.00" ID="C43861">Swedish </Semaphore>Medicines products agency (<Semaphore x="2228150" class="Disease or Finding" value="Microscopic Polyarteritis" score="1.00" ID="C70549">MPA</Semaphore>) reported by a <Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacist </Semaphore>from Italy reported by a <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional </Semaphore>nos (<Semaphore x="2665498" class="AnatomicStructure" value="Unspecified Anatomic Sites" score="1.00" ID="C13411">not otherwise specified</Semaphore>) from Sweden <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a 69-year old male patient who was treated with NovoNorm (<Semaphore x="1127038" class="Medicine" value="repaglinide" score="0.49" ID="282007">repaglinide</Semaphore>) on unknown dates for unknown indication and experienced "<Semaphore x="3285129" class="MedDRA LLT" value="Transaminases" score="1.00" ID="10054888">transaminases </Semaphore>elevated" beginning on 08-AUG 2012.Non Novo Nordisk suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>included <Semaphore x="1387652" class="Medicine" value="Zytiga" score="0.97" ID="194655">Zytiga </Semaphore>(<Semaphore x="15757" class="Medicine" value="abiraterone acetate" score="0.49" ID="194650">abiraterone acetate</Semaphore>) from 26-SEP 2011 to 07-NOV 2012.Medical history included metastased <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521">prostate cancer</Semaphore>.On 08-AUG 2012 the patient experienced <Semaphore x="3285129" class="MedDRA LLT" value="Transaminases" score="1.00" ID="10054888">transaminases </Semaphore>elevated. The Novonorm dose was raised during that time and was <Semaphore x="2125244" class="Disease or Finding" value="Lower Back Injury" score="1.00" ID="C35486">lowered </Semaphore>again. It was reported that for a week in <Semaphore x="2335153" class="Procedure" value="Optical Coherence Tomography" score="1.00" ID="C20828">OCT </Semaphore>2012, <Semaphore x="1387652" class="Medicine" value="Zytiga" score="0.97" ID="194655">Zytiga </Semaphore>was "deponated" and when <Semaphore x="1387652" class="Medicine" value="Zytiga" score="0.97" ID="194655">Zytiga </Semaphore>was introduced again this <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">resulted </Semaphore>in a raise in <Semaphore x="3285129" class="MedDRA LLT" value="Transaminases" score="1.00" ID="10054888">transaminases </Semaphore>and <Semaphore x="1387652" class="Medicine" value="Zytiga" score="0.97" ID="194655">Zytiga </Semaphore>was seponated on 07-NOV 2012. It was reported that the <Semaphore x="2424395" class="Procedure" value="Problem Tasting Food at its Worst" score="1.00" ID="C105545">issue </Semaphore>was elevation in transaminasis occurred after long time use of <Semaphore x="1387652" class="Medicine" value="Zytiga" score="0.97" ID="194655">Zytiga</Semaphore>.On an unknown date <Semaphore x="3057951" class="MedDRA LLT" value="Laboratory test" score="1.00" ID="10059938">laboratory tests </Semaphore>included: <Semaphore x="1469106" class="Procedure" value="Alanine Aminotransferase Measurement" score="1.00" ID="C64433">Alanine aminotransferase </Semaphore>4.43 (units unspecified) ref interval is less than 1.20 and <Semaphore x="1787567" class="Disease or Finding" value="Clinical Test Result" score="1.00" ID="C77140">test results </Semaphore>has been 4.43 - 1.73 - 3.71.- ukat/L)), <Semaphore x="1549211" class="Procedure" value="Aspartate Aminotransferase Measurement" score="1.00" ID="C64467">Aspartate aminotransferase </Semaphore>2.01 (units unspecified) ref interval is less than 0.76 and <Semaphore x="1787567" class="Disease or Finding" value="Clinical Test Result" score="1.00" ID="C77140">test result </Semaphore>has been 2.01 - 0.78 - 1.88 ukat/L)).Action taken to NovoNorm was reported as dose decreased.The overall <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event was reported as recovered.</narrativeincludeclinical>
				<reportercomment>Causality is stated to be possibly related but this is an umbrella evaluation for event and both products</reportercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>